VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
CB-03-10
Phase 1
Small molecule
C
Cosmo Technologies Ltd
1
Indications
1
Total Trials
1
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Maximum Tolerated Dose
Recruiting
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Maximum Tolerated Dose
Phase 1
Recruiting
Clinical
Trials by Indication
[1]
Maximum Tolerated Dose
1 trial
Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors
Recruiting
·
C
Cosmo Technologies Ltd
·
Phase 1
·
NCT03863145
·
90 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for CB-03-10. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
CB-03-10 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for CB-03-10. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Cosmo Technologies Ltd company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 1
[1]
Company
C
Cosmo Technologies Ltd
Related News